Production Method 1

50-70-4

50-99-7

609-06-3

10323-20-3

6027-89-0

583-50-6

Reaction Conditions

1.1 Catalysts: Platinum ,  Titania Solvents: Water ;  25 °C

Reference

Method for producing high-purity rare sugar from sugar alcohol through photocatalytic reaction using titania

, Japan, , ,

Production Method 2

9004-34-6

50-99-7

498-07-7

78797-67-8

67-47-0

141-46-8

Reaction Conditions

1.1 5 mbar, 370 °C → 765 °C

Reference

The interplay between chemistry and heat/mass transfer during the fast pyrolysis of cellulose

Westerhof, R. J. M.; Oudenhoven, S. R. G.; Marathe, P. S.; Engelen, M.; Garcia-Perez, M.; et al, Reaction Chemistry & Engineering, 2016, 1(5), 555-566

Production Method 3

50-99-7

83-48-7

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Water ;  2 h, reflux

Reference

A New 3,4-seco-Lupane Derivative from Lasianthus gardneri

Dallavalle, Sabrina; et al, Journal of Natural Products, 2004, 67(5), 911-913

Production Method 4

609-99-4

50-99-7

831-51-6

58-86-6

22416-58-6

49694-21-5

59-23-4

6860-47-5

47592-59-6

Reaction Conditions

1.1 Catalysts: Xylanase Solvents: Water ;  60 min, pH 9, 70 °C
1.2 Solvents: Water ;  15 min, 70 °C

Reference

Toward Valorization of the Effluent from Xylanase Prebleaching of Eucalypt Kraft Pulp Using a Nanofiltration Purification Step

Matos, Jose M. S.; et al, Industrial & Engineering Chemistry Research, 2023, 62(39), 16037-16047

D(+)-Glucose Raw materials

• Cellulose
• 3,5-Dinitrosalicylic acid
• D(-)-Sorbitol Standard

D(+)-Glucose Preparation Products

• (1R,2S,3S,4R,5R)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (498-07-7)
• L-Xylose (609-06-3)
• D-Arabinose (10323-20-3)
• Benzoic acid,3-amino-2-hydroxy-5-nitro- (831-51-6)
• 1,6-Anhydro-β-d-cellotriose (78797-67-8)
• D(+)-Xylose (58-86-6)
• 5-Hydroxymethylfurfural (67-47-0)
• Stigmasterol (83-48-7)
• Acetaldehyde, hydroxy-(9CI) (141-46-8)
• D(+)-Glucose (50-99-7)
• Xylotetraose (22416-58-6)
• Xylohexaose (49694-21-5)
• L-Gulose (6027-89-0)
• D-Galactose (59-23-4)
• Xylobiose (6860-47-5)
• D-Erythrose (583-50-6)
• Xylotriose (47592-59-6)

• 1. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Hexoses
• Natural Products and Extracts Plant Extracts Plant based Poraqueiba guianensis
• Natural Products and Extracts Plant Extracts Plant based Adesmia incana

D(+)-Glucose (50-99-7) in Pharmaceutical Applications: Key Roles and Research Advances

D(+)-Glucose (CAS 50-99-7), a fundamental monosaccharide, is pivotal in pharmaceutical and biomedical research due to its metabolic and therapeutic significance. As the primary energy source for cells, its applications span drug formulation, diagnostic agents, and metabolic disorder therapies. Recent studies highlight its role in glycosylation processes, enhancing drug stability and bioavailability. With the rise of biologics and mRNA vaccines, glucose derivatives are increasingly used as stabilizers in lyophilized formulations. Researchers also explore its potential in diabetes management, where modified glucose analogs act as insulin sensitizers. The compound’s safety profile (GRAS status) makes it a preferred excipient in parenteral nutrition and IV therapies, addressing user concerns about biocompatibility and efficacy.

50-99-7 D(+)-Glucose in Metabolic Research: Insights into Diabetes and Cancer Therapeutics

The intersection of D(+)-Glucose (50-99-7) and metabolic pathways has fueled breakthroughs in diabetes and oncology. Its isotopic-labeled variants (e.g., 13C-glucose) enable precise tracing of glycolytic flux in tumors, a hotspot in cancer metabolism research. Users searching for "glucose metabolism in cancer" will find studies on Warburg effect inhibition promising. Additionally, glucose-responsive insulin delivery systems, leveraging its enzymatic oxidation, are gaining traction for smart diabetes therapeutics. The compound’s role in PET imaging (FDG-PET) further underscores its diagnostic value, aligning with user interest in non-invasive disease monitoring.

D(+)-Glucose (50-99-7) as a Drug Excipient: Enhancing Stability and Delivery

In drug development, D(+)-Glucose (50-99-7) serves as a versatile excipient, addressing formulation challenges like osmolality adjustment and cryoprotection. Its inclusion in lyophilized biologics (e.g., monoclonal antibodies) prevents protein denaturation, a top concern for biopharma professionals. Searches for "glucose in vaccine stability" reveal its use in mRNA-based COVID-19 vaccines, where it maintains lipid nanoparticle integrity. Furthermore, glucose-based hydrogels are explored for controlled drug release, catering to demand for sustained-delivery systems. Regulatory approvals (USP/EP grades) ensure its suitability for parenteral and oral formulations, making it a staple in GMP-compliant production.

Innovative Therapies Using 50-99-7 D(+)-Glucose Derivatives: From Glycobiology to Neuroprotection

Derivatives of D(+)-Glucose (50-99-7), such as 2-deoxy-D-glucose, are at the forefront of glycobiology and neurodegenerative disease research. These compounds modulate glycosylation patterns, impacting cell signaling and immune responses—critical for autoimmune disease therapies. Users interested in "glucose analogs for Alzheimer’s" will find studies on ketogenic diets and brain energy metabolism compelling. Additionally, glucose-coated nanoparticles are being tested for targeted drug delivery to inflamed tissues, reflecting the trend toward precision medicine. The compound’s low toxicity and natural abundance further drive innovation in nutraceuticals and cosmeceuticals.

Safety and Regulatory Status of 50-99-7 D(+)-Glucose: Compliance in Pharma and Food Industries

The GRAS (Generally Recognized as Safe) designation of D(+)-Glucose (50-99-7) by the FDA and EFSA ensures its widespread use in pharmaceuticals and functional foods. Rigorous purity standards (e.g., ≥99.5% USP grade) address user queries about "medical-grade glucose safety." Its inclusion in WHO Essential Medicines List for rehydration therapy highlights global acceptance. Recent debates on high-fructose syrups have renewed interest in glucose as a safer sweetener in pediatric and geriatric formulations. Environmental sustainability—such as glucose from non-GMO starch hydrolysis—also resonates with eco-conscious consumers, aligning with green chemistry trends.

• 22224-55-1(alpha-D-mannoheptose)
• 23102-94-5(alpha-D-mannoheptose)
• 61091-67-6(alpha-D-mannoheptose)
• 13224-89-0(beta-D-Pyranose-2,3-Di-O-methylglucose)
• 56543-33-0((2S,3R,4S,5S,6R)-6-methyltetrahydro-2H-pyran-2,3,4,5-tetraol)
• 99508-72-2(7-deoxy-D-glycero-D-gluco-heptopyranose)
• 13405-48-6(beta-D-Pyranose-2,3-Di-O-methylglucose)
• 1949-76-4(alpha-D-mannoheptose)
• 162427-44-3(6-Deoxy-a-D-talose)
• 51348-50-6(alpha-Pyranose-L-Fucose)